From single nucleotide polymorphism to transcriptional mechanism a model for FRMD3 in diabetic nephropathy

Diabetes

Volumn 62, Issue 7, 2013, Pages 2605-2612

  Martini, Sebastian M ^a   Nair, Viji ^a   Patel, Sanjeevkumar R ^a   Eichinger, Felix ^a   Nelson, Robert G ^b   Weil, E Jennifer ^b   Pezzolesi, Marcus G ^c   Krolewski, Andrzej S ^c   Randolph, Ann ^a   Keller, Benjamin J ^d   Werner, Thomas ^a,e   Kretzler, Matthias ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c JOSLIN DIABETES CENTER   (United States)

^d EASTERN MICHIGAN UNIVERSITY   (United States)

^e Genomatix GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN; FRMD3 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ALLELE; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; FRMD3 GENE; FUNCTIONAL GENOMICS; GENE; HUMAN; HUMAN TISSUE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; BIOLOGICAL MODEL; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC TRANSCRIPTION; GENETICS; KIDNEY; METABOLISM; PATHOLOGY;

DIABETIC NEPHROPATHIES; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; KIDNEY; MODELS, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEINS;

EID: 84883690005     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db12-1416     Document Type: Article

References (47)

1. Freedman ML, Monteiro AN, Gayther SA, et al. Principles for the post-GWAS functional characterization of cancer risk loci. Nat Genet 2011;43:513-518
2. Fessele S, Maier H, Zischek C, Nelson PJ, Werner T. Regulatory context is a crucial part of gene function. Trends Genet 2002;18:60-63
3. Liu R, McEachin RC, States DJ. Computationally identifying novel NFkappa B-regulated immune genes in the human genome. Genome Res 2003;13:654-661
4. USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD, U.S. Renal Data System, 2010
5. Hasslacher C, Ritz E, Wahl P, Michael C. Similar risks of nephropathy in patients with type I or type II diabetes mellitus. Nephrol Dial Transplant 1989;4:859-863
6. Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 2005;28:164-176
7. Bloomgarden ZT. Diabetic nephropathy. Diabetes Care 2005;28:745-751
8. Freedman BI, Bostrom M, Daeihagh P, Bowden DW. Genetic factors in diabetic nephropathy. Clin J Am Soc Nephrol 2007;2:1306-1316
9. Conway BR, Maxwell AP. Genetics of diabetic nephropathy: are there clues to the understanding of common kidney diseases? Nephron Clin Pract 2009;112:c213-c221
10. Ichinose K, Kawasaki E, Eguchi K. Recent advancement of understanding pathogenesis of type 1 diabetes and potential relevance to diabetic nephropathy. Am J Nephrol 2007;27:554-564
11. Jennes I, Zuntini M, Mees K, et al. Identification and functional characterization of the human EXT1 promoter region. Gene 2012;492:148-159
12. Cohen CD, Klingenhoff A, Boucherot A, et al. Comparative promoter analysis allows de novo identification of specialized cell junction-associated proteins. Proc Natl Acad Sci USA 2006;103:5682-5687
13. Pezzolesi MG, Poznik GD, Mychaleckyj JC, et al.; DCCT/EDIC Research Group. Genome-wide association scan for diabetic nephropathy susceptibility genes in type 1 diabetes. Diabetes 2009;58:1403-1410
14. Maeda S, Araki S, Babazono T, et al. Replication study for the association between four Loci identified by a genome-wide association study on European American subjects with type 1 diabetes and susceptibility to diabetic nephropathy in Japanese subjects with type 2 diabetes. Diabetes 2010;59:2075-2079
15. Mooyaart AL, Valk EJ, van Es LA, et al. Genetic associations in diabetic nephropathy: a meta-analysis. Diabetologia 2011;54:544-553
16. Pezzolesi MG, Jeong J, Smiles A, et al. Family-based association analysis confirms the role of the chromosome 9q21.32 locus in the susceptibility of diabetic nephropathy. PLoS ONE. In press
17. Weil EJ, Fufaa G, Jones LI, et al. Effect of losartan on prevention and progression of early diabetic nephropathy in American Indians with type 2 diabetes. Diabetes. In press
18. Cohen CD, Frach K, Schlöndorff D, Kretzler M. Quantitative gene expression analysis in renal biopsies: a novel protocol for a high-throughput multicenter application. Kidney Int 2002;61:133-140
19. Thacker SG, Berthier CC, Mattinzoli D, Rastaldi MP, Kretzler M, Kaplan MJ. The detrimental effects of IFN-a on vasculogenesis in lupus are mediated by repression of IL-1 pathways: potential role in atherogenesis and renal vascular rarefaction. J Immunol 2010;185:4457-4469
20. Do JH, Choi DK. Clustering approaches to identifying gene expression patterns from DNA microarray data. Mol Cells 2008;25:279-288
21. Myers BD, Nelson RG, Tan M, et al. Progression of overt nephropathy in non-insulin-dependent diabetes. Kidney Int 1995;47:1781-1789
22. Weil EJ, Lemley KV, Mason CC, et al. Podocyte detachment and reduced glomerular capillary endothelial fenestration promote kidney disease in type 2 diabetic nephropathy. Kidney Int 2012;82:1010-1017
23. Cartharius K, Frech K, Grote K, et al. MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics 2005; 21:2933-2942
24. Werner T. Target gene identification from expression array data by promoter analysis. Biomol Eng 2001;17:87-94
25. Wiggins JE, Goyal M, Sanden SK, et al. Podocyte hypertrophy, "adaptation," and "decompensation" associated with glomerular enlargement and glomerulosclerosis in the aging rat: prevention by calorie restriction. J Am Soc Nephrol 2005;16:2953-2966
26. Patel SR, Dressler GR. Expression of Pax2 in the intermediate mesoderm is regulated by YY1. Dev Biol 2004;267:505-516
27. Berthier CC, Bethunaickan R, Gonzalez-Rivera T, et al. Cross-species transcriptional network analysis defines shared inflammatory responses in murine and human lupus nephritis. J Immunol 2012;189:988-1001
28. Maciel TT, Kempf H, Campos AH. Targeting bone morphogenetic protein signaling on renal and vascular diseases. Curr Opin Nephrol Hypertens 2010;19:26-31
29. Zhang Y, Zhang Q. Bone morphogenetic protein-7 and Gremlin: New emerging therapeutic targets for diabetic nephropathy. Biochem Biophys Res Commun 2009;383:1-3
30. Offit K. Personalized medicine: new genomics, old lessons. Hum Genet 2011;130:3-14
31. Jurado J, Ybarra J, Romeo JH, Garcia M, Zabaleta-Del-Olmo E. Angiotensinconverting enzyme gene single polymorphism as a genetic biomarker of diabetic peripheral neuropathy: longitudinal prospective study. J Diabetes Complications 2012;26:77-82
32. Kang P, Tian C, Jia C. Association of RAGE gene polymorphisms with type 2 diabetes mellitus, diabetic retinopathy and diabetic nephropathy. Gene 2012;500:1-9
33. Sandholm N, Salem RM, McKnight AJ, et al.; DCCT/EDIC Research Group. New susceptibility loci associated with kidney disease in type 1 diabetes. PLoS Genet 2012;8:e1002921
34. Benson CC, Zhou Q, Long X, Miano JM. Identifying functional single nucleotide polymorphisms in the human CArGome. Physiol Genomics 2011; 43:1038-1048
35. Nelson PJ, Werner T. Pathways and promoter networks analysis provides systems topology for systems biology approaches. Semin Nephrol 2010;30: 477-486
36. Jayapandian M, Chapman A, Tarcea VG, et al. Michigan Molecular Interactions (MiMI): putting the jigsaw puzzle together. Nucleic Acids Res 2007; 35:D566-D571
37. Feinberg AP. Epigenomics reveals a functional genome anatomy and a new approach to common disease. Nat Biotechnol 2010;28:1049-1052
38. Keller B, Martini S, Sedor J, Kretzler M. Linking variants from genomewide association analysis to function via transcriptional network analysis. Semin Nephrol 2010;30:177-184
39. Schadt EE, Monks SA, Drake TA, et al. Genetics of gene expression surveyed in maize, mouse and man. Nature 2003;422:297-302
40. Chen D, Zhao M, Mundy GR. Bone morphogenetic proteins. Growth Factors 2004;22:233-241
41. Ducy P, Karsenty G. The family of bone morphogenetic proteins. Kidney Int 2000;57:2207-2214
42. Zeisberg M, Kalluri R. Reversal of experimental renal fibrosis by BMP7 provides insights into novel therapeutic strategies for chronic kidney disease. Pediatr Nephrol 2008;23:1395-1398
43. Wang S, de Caestecker M, Kopp J, Mitu G, Lapage J, Hirschberg R. Renal bone morphogenetic protein-7 protects against diabetic nephropathy. J Am Soc Nephrol 2006;17:2504-2512
44. McKnight AJ, Pettigrew KA, Patterson CC, Kilner J, Sadlier DM, Maxwell AP; Warren 3/UK GoKinD Study Group. Investigation of the association of BMP gene variants with nephropathy in Type 1 diabetes mellitus. Diabet Med 2010;27:624-630
45. Hu C, Zhang R, Yu W, et al. CPVL/CHN2 genetic variant is associated with diabetic retinopathy in Chinese type 2 diabetic patients. Diabetes 2011;60: 3085-3089
46. Garrett MR, Pezzolesi MG, Korstanje R. Integrating human and rodent data to identify the genetic factors involved in chronic kidney disease. J Am Soc Nephrol 2010;21:398-405
47. Hesselberth JR, Chen X, Zhang Z, et al. Global mapping of protein-DNA interactions in vivo by digital genomic footprinting. Nat Methods 2009;6: 283-289